NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of “Moderate Buy” from Analysts

NeuroPace, Inc. (NASDAQ:NPCE) has been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $14.00.

Several equities research analysts have weighed in on NPCE shares. Wells Fargo & Company cut their target price on shares of NeuroPace from $20.00 to $15.00 and set an “overweight” rating on the stock in a report on Wednesday, August 14th. Morgan Stanley dropped their price objective on NeuroPace from $9.50 to $8.00 and set an “equal weight” rating on the stock in a research note on Monday, July 15th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $18.00 target price on shares of NeuroPace in a research note on Wednesday, August 14th.

Institutional Investors Weigh In On NeuroPace

A number of hedge funds and other institutional investors have recently bought and sold shares of NPCE. Financial Advocates Investment Management boosted its holdings in shares of NeuroPace by 50.0% in the 2nd quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock valued at $113,000 after buying an additional 5,000 shares during the last quarter. XTX Topco Ltd lifted its stake in NeuroPace by 56.1% in the second quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock valued at $182,000 after acquiring an additional 8,643 shares during the last quarter. Hillsdale Investment Management Inc. bought a new position in shares of NeuroPace in the 1st quarter valued at about $155,000. Rhumbline Advisers acquired a new position in shares of NeuroPace during the 2nd quarter worth about $111,000. Finally, Acadian Asset Management LLC raised its holdings in shares of NeuroPace by 46.0% in the 2nd quarter. Acadian Asset Management LLC now owns 68,918 shares of the company’s stock valued at $520,000 after purchasing an additional 21,703 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

NeuroPace Stock Performance

Shares of NASDAQ:NPCE opened at $6.21 on Friday. The stock has a market capitalization of $178.65 million, a P/E ratio of -5.22 and a beta of 1.78. The company has a current ratio of 6.37, a quick ratio of 5.47 and a debt-to-equity ratio of 5.97. NeuroPace has a 1-year low of $5.73 and a 1-year high of $18.15. The business has a 50-day moving average price of $7.12 and a two-hundred day moving average price of $8.70.

NeuroPace (NASDAQ:NPCE) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.03. NeuroPace had a negative return on equity of 195.26% and a negative net margin of 41.63%. The business had revenue of $19.26 million during the quarter, compared to the consensus estimate of $18.30 million. During the same quarter in the prior year, the company posted ($0.36) earnings per share. The firm’s revenue was up 16.6% on a year-over-year basis. Equities analysts predict that NeuroPace will post -1.08 earnings per share for the current year.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.